DelMar Pharmaceuticals Announces Fast Track Designation for VAL-083 in Recurrent Glioblastoma December 26, 2017 • 5:30 AM EST
DelMar Presents Positive Interim Results from VAL-083 Study in MGMT-unmethylated Recurrent GBM at The Society for NeuroOncology Annual Meeting November 21, 2017 • 3:06 PM EST
DelMar Pharmaceuticals Announces First Quarter Fiscal Year 2018 Financial Results November 13, 2017 • 6:14 PM EST
DelMar Pharmaceuticals Appoints Saiid Zarrabian as Interim Chief Executive Officer November 7, 2017 • 4:05 PM EST
DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Component of Combination Chemotherapy Regimens for the Treatment of Solid Tumors including Brain and Ovarian Cancer October 31, 2017 • 5:30 AM EDT
DelMar Pharmaceuticals Presents Poster at AACR's Ovarian Cancer Special Conference on the Mechanistic Rationale for VAL-083 Overcoming Treatment Resistance in Ovarian Cancer October 3, 2017 • 5:30 AM EDT
DelMar Pharmaceuticals to Present at AACR Special Conference on Ovarian Cancer September 27, 2017 • 5:30 AM EDT
DelMar Pharmaceuticals Announces Closing Of $10 Million Registered Direct Offering Priced At-The-Market September 22, 2017 • 2:20 PM EDT
DelMar Pharmaceuticals Announces $10 Million Registered Direct Offering Priced At-The-Market September 20, 2017 • 3:31 PM EDT